1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA)
Thomas J Ford, Bethany Stanley, Novalia Sidik, Richard Good, Paul Rocchiccioli, Margaret McEntegart, Stuart Watkins, Hany Eteiba, Aadil Shaukat, Mitchell Lindsay, Keith Robertson, Stuart Hood, Ross McGeoch, Robert McDade, Eric Yii, Peter McCartney, David Corcoran, Damien Collison, Christopher Rush, Naveed Sattar, Alex McConnachie, Rhian M Touyz, Keith G Oldroyd, Colin Berry, Thomas J Ford, Bethany Stanley, Novalia Sidik, Richard Good, Paul Rocchiccioli, Margaret McEntegart, Stuart Watkins, Hany Eteiba, Aadil Shaukat, Mitchell Lindsay, Keith Robertson, Stuart Hood, Ross McGeoch, Robert McDade, Eric Yii, Peter McCartney, David Corcoran, Damien Collison, Christopher Rush, Naveed Sattar, Alex McConnachie, Rhian M Touyz, Keith G Oldroyd, Colin Berry
Abstract
Objectives: The aim of this study was to test the hypothesis that invasive coronary function testing at time of angiography could help stratify management of angina patients without obstructive coronary artery disease.
Background: Medical therapy for angina guided by invasive coronary vascular function testing holds promise, but the longer-term effects on quality of life and clinical events are unknown among patients without obstructive disease.
Methods: A total of 151 patients with angina with symptoms and/or signs of ischemia and no obstructive coronary artery disease were randomized to stratified medical therapy guided by an interventional diagnostic procedure versus standard care (control group with blinded interventional diagnostic procedure results). The interventional diagnostic procedure-facilitated diagnosis (microvascular angina, vasospastic angina, both, or neither) was linked to guideline-based management. Pre-specified endpoints included 1-year patient-reported outcome measures (Seattle Angina Questionnaire, quality of life [EQ-5D]) and major adverse cardiac events (all-cause mortality, myocardial infarction, unstable angina hospitalization or revascularization, heart failure hospitalization, and cerebrovascular event) at subsequent follow-up.
Results: Between November 2016 and December 2017, 151 patients with ischemia and no obstructive coronary artery disease were randomized (n = 75 to the intervention group, n = 76 to the control group). At 1 year, overall angina (Seattle Angina Questionnaire summary score) improved in the intervention group by 27% (difference 13.6 units; 95% confidence interval: 7.3 to 19.9; p < 0.001). Quality of life (EQ-5D index) improved in the intervention group relative to the control group (mean difference 0.11 units [18%]; 95% confidence interval: 0.03 to 0.19; p = 0.010). After a median follow-up duration of 19 months (interquartile range: 16 to 22 months), major adverse cardiac events were similar between the groups, occurring in 9 subjects (12%) in the intervention group and 8 (11%) in the control group (p = 0.803).
Conclusions: Stratified medical therapy in patients with ischemia and no obstructive coronary artery disease leads to marked and sustained angina improvement and better quality of life at 1 year following invasive coronary angiography. (Coronary Microvascular Angina [CorMicA]; NCT03193294).
Keywords: coronary physiology; elective coronary angiography; microvascular angina; stable angina pectoris; stratified medicine; vasospastic angina.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
References
- Patel M.R., Peterson E.D., Dai D. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;362:886–895.
- Maddox T.M., Stanislawski M.A., Grunwald G.K. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014;312:1754–1763.
- Tavella R., Cutri N., Tucker G., Adams R., Spertus J., Beltrame J.F. Natural history of patients with insignificant coronary artery disease. Eur Heart J Qual Care Clin Outcomes. 2016;2:117–124.
- Jespersen L., Hvelplund A., Abildstrom S.Z. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33:734–744.
- Suda A., Takahashi J., Hao K. Coronary functional abnormalities in patients with angina and nonobstructive coronary artery disease. J Am Coll Cardiol. 2019;74:2350–2360.
- Ford T.J., Berry C., De Bruyne B. Physiological predictors of acute coronary syndromes: emerging insights from the plaque to the vulnerable patient. J Am Coll Cardiol Intv. 2017;10:2539–2547.
- Ford T.J., Corcoran D., Oldroyd K.G. Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. Am Heart J. 2018;201:86–94.
- Ford T.J., Stanley B., Good R. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol. 2018;72:2841–2855.
- Rose G., McCartney P., Reid D.D. Self-administration of a questionnaire on chest pain and intermittent claudication. Br J Prev Soc Med. 1977;31:42–48.
- Task Force M., Montalescot G., Sechtem U. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.
- Beltrame J.F., Crea F., Kaski J.C. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38:2565–2568.
- Spertus J.A., Winder J.A., Dewhurst T.A. Development and evaluation of the Seattle Angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25:333–341.
- Chan P.S., Jones P.G., Arnold S.A., Spertus J.A. Development and validation of a short version of the Seattle Angina Questionnaire. Circ Cardiovasc Qual Outcomes. 2014;7:640–647.
- Spertus J.A., Arnold S.V. The evolution of patient-reported outcomes in clinical trials and management of patients with coronary artery disease: 20 years with the Seattle Angina Questionnaire. JAMA Cardiol. 2018;3:1035–1036.
- Spertus J.A., Winder J.A., Dewhurst T.A., Deyo R.A., Fihn S.D. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol. 1994;74:1240–1244.
- Al-Lamee R., Thompson D., Dehbi H.M. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31–40.
- Sullivan M.D., Ciechanowski P.S., Russo J.E. Angina pectoris during daily activities and exercise stress testing: the role of inducible myocardial ischemia and psychological distress. Pain. 2008;139:551–561.
- The MRC Framework for the Development, Design and Analysis of Stratified Medicine Research. Medical Research Council; London: 2018.
- Fearon W.F., Okada K., Kobashigawa J.A. Angiotensin-converting enzyme inhibition early after heart transplantation. J Am Coll Cardiol. 2017;69:2832–2841.
- Ong P., Athanasiadis A., Sechtem U. Pharmacotherapy for coronary microvascular dysfunction. Eur Heart J Cardiovasc Pharmacother. 2015;1:65–71.
- Anderson L., Thompson D.R., Oldridge N. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016;1
- Lean M.E.J., Leslie W.S., Barnes A.C. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541–551.
- Kirtane A.J. The importance of listening to patients: the Seattle Angina Questionnaire. JAMA Cardiology. 2018;3:1037.
- Kirtane A.J. ORBITA2. Circulation. 2018;138:1793–1796.
- Petrie K.J., Weinman J., Sharpe N., Buckley J. Role of patients’ view of their illness in predicting return to work and functioning after myocardial infarction: longitudinal study. BMJ. 1996;312:1191–1194.
- Aziz A., Hansen H.S., Sechtem U., Prescott E., Ong P. Sex-related differences in vasomotor function in patients with angina and unobstructed coronary arteries. J Am Coll Cardiol. 2017;70:2349–2358.
- Kaski J.C., Crea F., Gersh B.J., Camici P.G. Reappraisal of ischemic heart disease. Circulation. 2018;138:1463–1480.
- Bogaert M.G. Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations. Clin Pharmacokinet. 1987;12:1–11.
- Ford T.J., Rocchiccioli P., Good R. Systemic microvascular dysfunction in microvascular and vasospastic angina. Eur Heart J. 2018;39:4086–4097.
- Sheikh A.R., Zeitz C.J., Rajendran S., Di Fiore D.P., Tavella R., Beltrame J.F. Clinical and coronary haemodynamic determinants of recurrent chest pain in patients without obstructive coronary artery disease—a pilot study. Int J Cardiol. 2018;267:16–21.
- Williams M.C., Hunter A., Shah A. Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial. Heart. 2017;103:995–1001.
Source: PubMed